Pharmacological effects of osimertinib on a chicken chorioallantoic membrane xenograft model with the EGFR exon‐19‐deleted advanced NSCLC mutation
Non‐small cell lung cancer (NSCLC) affects 10–50% of patients with epidermal growth factor receptor (EGFR) mutations. Osimertinib is a third‐generation EGFR tyrosine kinase inhibitor (TKI) that radically changes the outcome of patients with tumors bearing EGFR sensitizing or EGFR T790M resistance mu...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Wiley
2025-05-01
|
| Schriftenreihe: | FEBS Open Bio |
| Schlagworte: | |
| Online-Zugang: | https://doi.org/10.1002/2211-5463.13970 |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|
